AR099563A1 - PÉPTIDOS HORQUILLA b CON PROPIEDADES ANTIVIRALES CONTRA EL VIRUS DENGUE - Google Patents
PÉPTIDOS HORQUILLA b CON PROPIEDADES ANTIVIRALES CONTRA EL VIRUS DENGUEInfo
- Publication number
- AR099563A1 AR099563A1 ARP150100549A ARP150100549A AR099563A1 AR 099563 A1 AR099563 A1 AR 099563A1 AR P150100549 A ARP150100549 A AR P150100549A AR P150100549 A ARP150100549 A AR P150100549A AR 099563 A1 AR099563 A1 AR 099563A1
- Authority
- AR
- Argentina
- Prior art keywords
- peptides
- dengue virus
- fork
- properties against
- antiviral properties
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
- A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24133—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Virology (AREA)
- Inorganic Chemistry (AREA)
- Nanotechnology (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
La presente está relacionada con péptidos sintéticos estructuralmente constreñidos, que han sido optimizados para la formación de estructura horquilla beta. Dichos péptidos son capaces de inhibir o atenuar la infección por el virus Dengue (DENV). Incluye también composiciones farmacéuticas que contienen estos péptidos sintéticos, las que son útiles para la prevención y/o el tratamiento de las infecciones causadas por DENV. De igual forma, provee un método de tratamiento de las infecciones causadas por este virus.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CUP2014000026A CU20140026A7 (es) | 2014-03-03 | 2014-03-03 | Péptidos horquilla beta con propiedades antivirales contra el virus dengue |
Publications (1)
Publication Number | Publication Date |
---|---|
AR099563A1 true AR099563A1 (es) | 2016-08-03 |
Family
ID=53008223
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP150100549A AR099563A1 (es) | 2014-03-03 | 2015-02-24 | PÉPTIDOS HORQUILLA b CON PROPIEDADES ANTIVIRALES CONTRA EL VIRUS DENGUE |
Country Status (14)
Country | Link |
---|---|
US (1) | US9896482B2 (es) |
EP (1) | EP3115056B1 (es) |
JP (1) | JP6854644B2 (es) |
KR (1) | KR102325400B1 (es) |
CN (1) | CN106132981B (es) |
AR (1) | AR099563A1 (es) |
AU (1) | AU2015226580B2 (es) |
CA (1) | CA2940078C (es) |
CU (1) | CU20140026A7 (es) |
ES (1) | ES2733648T3 (es) |
MX (1) | MX363745B (es) |
MY (1) | MY181033A (es) |
PH (1) | PH12016501715A1 (es) |
WO (1) | WO2015131858A2 (es) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017189988A1 (en) * | 2016-04-29 | 2017-11-02 | Araim Pharmaceuticals, Inc. | Tissue protective peptides for preventing and treating diseases and disorders associated with tissue damage |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CU23586A1 (es) * | 2005-11-22 | 2010-10-30 | Ct Ingenieria Genetica Biotech | Métodos y proteínas para el tratamiento profiláctico y/o terapéutico de los cuatro serotipos del virus de dengue y otros flavivirus |
CU23632A1 (es) * | 2006-04-28 | 2011-02-24 | Ct Ingenieria Genetica Biotech | Métodos para la identificación de candidatos terapéuticos contra enfermedades causadas por flavivirus y moléculas antivirales. |
CU23630A1 (es) * | 2006-10-30 | 2011-02-24 | Ct Ingenieria Genetica Biotech | Moléculas peptídicas quiméricas con propiedades antivirales contra los virus de la familia flaviviridae |
CU20080028A6 (es) * | 2008-02-29 | 2011-02-24 | Ct Ingenieria Genetica Biotech | Compuestos químicos obtenidos in silico para la preparación de composiciones farmacéuticas para atenuar o inhibir la infección por virus dengue y otros flavivirus |
-
2014
- 2014-03-03 CU CUP2014000026A patent/CU20140026A7/es unknown
-
2015
- 2015-02-24 AR ARP150100549A patent/AR099563A1/es unknown
- 2015-02-26 ES ES15718758T patent/ES2733648T3/es active Active
- 2015-02-26 KR KR1020167026665A patent/KR102325400B1/ko active IP Right Grant
- 2015-02-26 US US15/119,058 patent/US9896482B2/en active Active
- 2015-02-26 WO PCT/CU2015/000002 patent/WO2015131858A2/es active Application Filing
- 2015-02-26 MY MYPI2016703158A patent/MY181033A/en unknown
- 2015-02-26 AU AU2015226580A patent/AU2015226580B2/en active Active
- 2015-02-26 CA CA2940078A patent/CA2940078C/en active Active
- 2015-02-26 EP EP15718758.4A patent/EP3115056B1/en active Active
- 2015-02-26 MX MX2016011420A patent/MX363745B/es active IP Right Grant
- 2015-02-26 JP JP2016555504A patent/JP6854644B2/ja active Active
- 2015-02-26 CN CN201580011814.8A patent/CN106132981B/zh active Active
-
2016
- 2016-08-31 PH PH12016501715A patent/PH12016501715A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
MX2016011420A (es) | 2016-11-16 |
WO2015131858A3 (es) | 2015-10-29 |
PH12016501715B1 (en) | 2016-12-19 |
EP3115056A2 (en) | 2017-01-11 |
CA2940078A1 (en) | 2015-09-11 |
US9896482B2 (en) | 2018-02-20 |
JP2017509619A (ja) | 2017-04-06 |
MY181033A (en) | 2020-12-16 |
CN106132981A (zh) | 2016-11-16 |
BR112016019672A2 (pt) | 2017-10-24 |
KR20160127097A (ko) | 2016-11-02 |
CU20140026A7 (es) | 2015-11-27 |
KR102325400B1 (ko) | 2021-11-12 |
WO2015131858A2 (es) | 2015-09-11 |
AU2015226580B2 (en) | 2018-11-08 |
ES2733648T3 (es) | 2019-12-02 |
PH12016501715A1 (en) | 2016-12-19 |
CN106132981B (zh) | 2019-11-12 |
US20170152290A1 (en) | 2017-06-01 |
AU2015226580A1 (en) | 2016-09-15 |
EP3115056B1 (en) | 2019-04-03 |
JP6854644B2 (ja) | 2021-04-07 |
CA2940078C (en) | 2020-11-17 |
MX363745B (es) | 2019-04-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20180243A1 (es) | Composiciones que comprenden cepas bacterianas | |
CL2018001349A1 (es) | Composiciones que comprenden cepas bacterianas | |
CL2018001367A1 (es) | Composiciones que comprenden cepas bacterianas | |
PH12017500393A1 (en) | Pyrrolopyrimidines for use in influenza virus infection | |
PH12017500207B1 (en) | Indoles for use in influenza virus infection | |
CR20160123A (es) | Inhibidores de polimerasa hcv | |
CR20160337A (es) | Nuevas heteroarildihidropirimidinas 6-fusionadas para el tratamiento y la profilaxis de la infección por virus de la hepatitis b | |
EA201791460A1 (ru) | N4-гидроксицитидин и связанные с ним производные и варианты противовирусного применения | |
NZ727392A (en) | Methods of preparing substituted nucleotide analogs | |
MA50264A (fr) | Méthodes de traitement des infections de type hépatite b | |
BR112018069974A2 (pt) | compostos de tiazolida para o tratamento de infecções virais | |
CR20160178A (es) | Derivados de desoxinojirimicina y sus métodos de uso | |
UY36221A (es) | Derivados de isoindolinona | |
ECSP19026702A (es) | Compuestos novedosos para el tratamiento de enfermedades parasitarias | |
PH12016502001A1 (en) | Novel bacteriophage and composition comprising same | |
CO2020005420A2 (es) | Compuestos antibacterianos | |
PE20170185A1 (es) | Composiciones farmaceuticas para tratar enfermedades infecciosas | |
CL2016001977A1 (es) | Composición que comprende igm derivada de plasma y su uso para el tratamiento o prevención de afecciones inmunitarias. | |
PH12017500816A1 (en) | Long acting pharmaceutical compositions for hepatitis c | |
PH12017500820A1 (en) | Combination long acting compositions and methods for hepatitis c | |
PH12016502000A1 (en) | Novel bacteriophage and composition comprising same | |
AR099563A1 (es) | PÉPTIDOS HORQUILLA b CON PROPIEDADES ANTIVIRALES CONTRA EL VIRUS DENGUE | |
EA201700097A1 (ru) | Пептид для лечения сахарного диабета 2-го типа и его осложнений | |
EA201301340A1 (ru) | Фармацевтическая композиция, обладающая нейропротекторным действием, её применение и способы повышения жизнеспособности и профилактики или лечения цереброваскулярных и нейродегенеративных заболеваний | |
TH1601005264A (es) |